



2024 NCODA International Fall Summit:

Essential CE Information

CE Registration:

- Please make sure to register for the 2024 NCODA International Fall Summit CEs via this link: <https://www.lecturepanda.com/r/2024NCODAFallSummit>
 - After registering for your CE, you should receive a confirmation email with a unique link. **Please DO NOT share this link with anyone as it is unique to your own profile.**
- You may also register for the 2024 NCODA International Fall summit CEs via this QR code:



CE Pre-assessment:

- After registering for your selected CEs, please make sure to complete each of your CE sessions' Pre-assessment **BEFORE** the start of each of those CE sessions
 - This is because the Pre-assessment will automatically close out 15 minutes **AFTER** each CE session, in order to prevent obtaining invalid data from participants completing the Pre-assessment after the CE session has ended

Obtaining CE Credit:

- Credit requirements must be completed within 60 days of the program activity date: **December 23rd, 2024**
- Upon completion, credit will be transmitted electronically to ACPE
 - If you are a nurse or physician, NCODA has partnered with Partners for Advancing Clinical Education (PACE) to expand CE accreditation for nurses and physicians
 - Please refer to the "PACE Handout" for more information

2024 NCODA Fall Summit

Physician and Registered Nurse Sessions CE Information

October 23-25, 2024 | Orlando, FL

Jointly provided by Partners for Advancing Clinical Education (PACE) and NCODA

Target Audience

This conference is intended for oncology healthcare providers that include; pharmacists, pharmacy technicians, physicians and nurses who care for patients within oncology.

Individual CME/CNE Session Educational Objectives

Upon completion of each session, participants should be able to:

Staying Up-to-date with Upper Gastrointestinal Malignancies

0.75 AMA PRA Category 1 Credit™ and 0.75 ANCC contact hour

- Identify how the histologic differences across the upper gastrointestinal (GI) cancers affect incidence of various biomarkers
- Determine an appropriate first-line treatment regimen for early-stage or metastatic upper GI cancers based on recent literature
- Recognize a supportive care prevention and management plan for patients with upper GI cancers receiving newer systemic therapies

Alphabet Soup: Unlocking Acronyms in Pathology and Cancer Care

0.75 ANCC contact hour

- Describe acronyms related to testing and staging for cancer
- Identify acronyms related to actionable mutations used in the diagnosis and treatment of cancer
- Differentiate treatment options for various cancers based on molecular targets

A Review of Prostate Cancer & Recent Updates in the Treatment of Metastatic Prostate Cancer

1.0 AMA PRA Category 1 Credit™ and 1.0 ANCC contact hour

- Explain the background of prostate cancer
- Outline the elements of a prostate cancer diagnosis
- Discuss the recent updates in metastatic castration-resistant prostate cancer treatment
- Describe the adverse effect profile of the medications recently approved for metastatic castration-resistant prostate cancer

Championing Patient Care: Highlighting the Varied Roles of Nurses in Oral Anticancer Therapy

1.0 ANCC contact hour

- Identify touchpoints to track for managing patients taking oral anticancer agents
- Compare funding resources available for patients based on their prescription insurance coverage
- Describe resources to help nurses and the Medically integrated care team care for patients taking OAM

Exploring the Medicare Landscape: Understanding the Domino Effect

1.0 AMA PRA Category 1 Credit™ and 1.0 ANCC contact hour

- Review financial navigation interventions that help mitigate the experience of financial toxicity when high-dollar pharmaceuticals are used
- Discuss the advantages and disadvantages the Medicare Prescription Payment Program will have on Medicare Part D beneficiaries
- Recognize the impact of new IRA changes related to oral oncolytics, including possible price fluctuations, smoothing program implementation, and policy regulations
- Identify policy changes surrounding prior authorization, coding changes, and enhancements of step therapies (immunotherapies)

Low Grade Serous Ovarian Cancer Overview and Patient Management

1.0 AMA PRA Category 1 Credit™ and 1.0 ANCC contact hour

- Describe the epidemiology (incidence, prevalence, risk factors) and prognosis associated with LGSOC, and the key characteristics distinguishing LGSOC from other types of ovarian cancer
- Discuss common symptoms, clinical presentation, and diagnostics tools and criteria to accurately diagnose LGSOC
- Review guideline-based standard treatment protocols for LGSOC, toxicities, and management strategies for available therapies
- Explain the role of emerging treatment modalities in the management of LGSOC while identifying ongoing challenges and potential future directions in the treatment and management of patients with LGSOC

Voice of Resilience: A Patient's Perspective on Advocating for Mental Health in Oncology Care

1.0 ANCC contact hour

- Describe the impact mental health has on a cancer patient's prognosis, quality of life, and long-term well-being
- Identify the barriers cancer patients face in receiving mental healthcare
- Observe through the eyes of a cancer survivor on how patient perspectives can guide effective mental health advocacy and support nursing practice

Addressing Cancer Disparities and Social Determinants of Health in Unique Rural Populations

0.75 AMA PRA Category 1 Credit™ and 0.75 ANCC contact hour

- Identify national rankings and overall cancer incidence and mortality as it relates to the state of Kentucky as well as the Appalachian region of the state
- Describe key health behaviors and social determinants of health driving Kentucky's cancer disparities
- Discuss the ACTION Program as it relates to addressing cancer disparities within Appalachian Kentucky and how a similar model may be utilized to address other populations' unique cancer disparities

Precision Medicine in Lung Cancer: The Role of the Medically Integrated Team

1.0 AMA PRA Category 1 Credit™ and 1.0 ANCC contact hour

- Discuss the role of targeted therapy and immunotherapy in the treatment of patients diagnosed with Stage III lung cancer

- Review the clinical evidence supporting adjuvant therapies for EGFR-mutated lung cancer ALK-rearranged lung cancer
- Describe what is next generation sequencing and application to lung cancer treatment in the adjuvant setting
- Detail a multidisciplinary approach to navigate patients through molecular profiling, interpretation of results, and proactive interdisciplinary processes for obtaining targeted therapy

New Options for Patients: Latest Oncology Drug Trends

1.0 AMA PRA Category 1 Credit™ and 1.0 ANCC contact hour

- Identify the US United States (US) trends in the Oncology oncology market
- Discuss emerging research and development for various cancer trials and disease states
- Compare and contrast Global vs US spending on Oncology treatment regimens
- Recognize the use of scientific advances in oncology to increase patient access to care

Exploring Bispecifics and CAR-T Therapies

1.0 AMA PRA Category 1 Credit™ and 1.0 ANCC contact hour

- Identify the current indications of CAR T-cell therapy and bispecifics in B-cell non-Hodgkin lymphomas
- Summarize the existing challenges associated with delivery of care with CAR T-cell and bispecific therapies
- Discuss therapeutic options to manage relapse post-CAR T-cell therapy
- Recognize the future implications for CAR T-cell and bispecific therapies

Faculty and Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Summit Chairs/Steering Committee	Relevant Financial Relationships
Jacqueline Caban, MPS	Has no relevant financial relationships.
Chris Elder, PharmD, BCOP	Advisory Board: Boehringer Ingelheim, Sanofi, Novartis, Eisai, Janssen, Pfizer
Amanda McCauley, BSN, RN, OCN	Has no relevant financial relationships.
Vonda McClendon, CPhT	Has no relevant financial relationships.
Apiew Ojulu, PharmD, MS	Has no relevant financial relationships.
Debbie Shapert, RN, MS, OCN	Has no relevant financial relationships.
Makenna Smack, PharmD, BCOP	Has no relevant financial relationships.
Natalie Dickson, MD, MMHC, FASCO, FACP,	Has no relevant financial relationships.
Gury Doshi, MD	Has no relevant financial relationships.
Scott Freeswick, PharmD, MS	Advisory Board: Orhard Therapeutics, Taiho Oncology,

	Pharmacosmos, Fresenius, Sanofi/Genzyme
Lucio Gordan, MD	Advisory Board: Genentech
Stacey McCullough, PharmD	Has no relevant financial relationships.
Michael Reff, RPh, MBA	Speaker: Pfizer, Janssen

Faculty	Relevant Financial Relationships
Diana Cauley, PharmD, BCOP, MD Anderson	Has no relevant financial relationships.
Nathan Vanderford, PhD, MBA	Has no relevant financial relationships.
Katie Long Richardson, PharmD, BCOP	Has no relevant financial relationships.
Mary Anderson, BSN, RN, OCN, NCODA	Has no relevant financial relationships.
Elizabeth Bettencourt, MSN, RN, OCN	Has no relevant financial relationships.
Brittni Dissen, BSN, RN, OCN,	Has no relevant financial relationships.
Dana Slusher, BSN, RN, OCN	Has no relevant financial relationships.
Mohamed A. Kharfan-Dabaja, MD, MBA, FACP	Principal Investigator: BMS, Novartis, Pharmacyclics; Speaker: Kite Pharma
Bobbi Buell, MBA	Employee and Stockholder: RxVantage; Consultant: Genentech, Servier, Avyxa, Novartis; Speaker: Genentech, Avyxa, Novartis
Dan Sherman	Consultant: TailoMed; Speaker: Taiho Pharmaceuticals
Sarah Hayward, PharmD, BCOP	Advisor: Merck, AbbVie, Seagen/Genmab, GSK, Verastem
Doug Long	Speaker: Apotex, Optisource, GSMM, AMCP, SAMPA, ARTIA
Kevin Hicks, PharmD, PhD, FCCP	Consultant: ARUP, Jackson
Theresa Boyle, MD, PhD	Principal Investigator and Speaker: BMS
Donna Gallenstein, BSN, RN, GERO-BC	Has no relevant financial relationships.
Daniel Melzer, PharmD, BCOP	Advisory Board: Daichii Sankyo, Takeda; Speaker: Jazz Pharmaceuticals; Other: Dedham Group and OncoGenius Solutions
Sonam Puri, MD	Advisory Board: Pfizer, Takeda, BMS, Novocure, Oncohost
Courtney Cavalieri, PharmD, BCOP	Advisor: Pfizer
Nancy Gregory, MBA, CFE, CCEP	Has no relevant financial relationships.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and NCODA. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this live activity for a maximum of 6.5 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 6.5 contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions for Credit

CE Credit for the NCODA 2024 Spring Forum can be claimed through the LecturePanda platform. To register, please visit: <https://www.lecturepanda.com/r/2024NCODAFallSummit>

- Credit requirements must be completed within 60 days of the program activity date.
- CE code will be displayed at the end of the session. This code will be required to receive credit.